GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » e-Therapeutics PLC (LSE:ETX) » Definitions » Ending Cash Position

e-Therapeutics (LSE:ETX) Ending Cash Position : £24.85 Mil (As of Jul. 2023)


View and export this data going back to 2007. Start your Free Trial

What is e-Therapeutics Ending Cash Position?

e-Therapeutics's Ending Cash Position for the quarter that ended in Jul. 2023 was £24.85 Mil.

e-Therapeutics's quarterly Ending Cash Position increased from Jul. 2022 (£21.56 Mil) to Jan. 2023 (£31.69 Mil) but then declined from Jan. 2023 (£31.69 Mil) to Jul. 2023 (£24.85 Mil).

e-Therapeutics's annual Ending Cash Position increased from Jan. 2021 (£7.01 Mil) to Jan. 2022 (£11.35 Mil) and increased from Jan. 2022 (£11.35 Mil) to Jan. 2023 (£31.69 Mil).

e-Therapeutics Ending Cash Position Historical Data

The historical data trend for e-Therapeutics's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

e-Therapeutics Ending Cash Position Chart

e-Therapeutics Annual Data
Trend Jan14 Jan15 Jan16 Jan17 Jan18 Jan19 Jan20 Jan21 Jan22 Jan23
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.90 3.84 7.01 11.35 31.69

e-Therapeutics Semi-Annual Data
Jan14 Jul14 Jan15 Jul15 Jan16 Jul16 Jan17 Jul17 Jan18 Jul18 Jan19 Jul19 Jan20 Jul20 Jan21 Jul21 Jan22 Jul22 Jan23 Jul23
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 25.57 11.35 21.56 31.69 24.85

e-Therapeutics Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

e-Therapeutics's Ending Cash Position for the fiscal year that ended in Jan. 2023 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=11.346+20.343
=31.69

e-Therapeutics's Ending Cash Position for the quarter that ended in Jul. 2023 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=31.689+-6.844
=24.85

e-Therapeutics Ending Cash Position Related Terms

Thank you for viewing the detailed overview of e-Therapeutics's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

e-Therapeutics (LSE:ETX) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » e-Therapeutics PLC (LSE:ETX) » Definitions » Ending Cash Position
Comparable Companies
LSE:POLB LSE:SAR LSE:AREC LSE:OBD LSE:TRX LSE:DEST LSE:SBTX LSE:HEMO LSE:OPTI LSE:C4XD OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XKRX:068270 BNTX ALNY
Traded in Other Exchanges
ETXPF:USA
Address
4 Kingdom Street, Paddington, London, GBR, W2 6BD
Website
https://www.etherapeutics.co.uk
e-Therapeutics PLC is a drug discovery company. Its ambition is to transform the drug discovery process, leveraging its computational network biology platform (drug discovery) to find novel targets to address mechanisms underpinning complex disease. l company activities are carried out in the UK.

e-Therapeutics (LSE:ETX) Headlines

From GuruFocus

Eaton Vance Municipal Income 2028 Term Trust Announces Telephonic Annual Meeting Of Shareholders On November 12, 2021

By PRNewswire PRNewswire • 11-02-2021